Biotransformation differences of ginsenoside compound K mediated by the gut microbiota from diabetic patients and healthy subjects.
10.1016/S1875-5364(23)60402-9
- Author:
Sutianzi HUANG
1
,
2
,
3
;
Li SHAO
4
;
Manyun CHEN
1
,
5
;
Lin WANG
1
,
5
;
Jing LIU
1
,
5
;
Wei ZHANG
1
,
2
,
6
;
Weihua HUANG
1
,
2
,
7
Author Information
1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
2. Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China
3. The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.
4. Department of Pharmacognosy, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410128, China.
5. Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China.
6. The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, China. Electronic address: csuzhangwei@csu.edu.cn.
7. The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, China. Electronic address: endeavor34852@csu.edu.cn.
- Publication Type:Journal Article
- Keywords:
Biotransformation;
Diabetes;
Ginsenoside compound K;
Gut microbiota
- MeSH:
Humans;
Gastrointestinal Microbiome/genetics*;
Chromatography, Liquid/methods*;
Healthy Volunteers;
RNA, Ribosomal, 16S;
Feces/microbiology*;
Tandem Mass Spectrometry;
Biotransformation;
Diabetes Mellitus, Type 2/drug therapy*
- From:
Chinese Journal of Natural Medicines (English Ed.)
2023;21(10):723-729
- CountryChina
- Language:English
-
Abstract:
Many natural products can be bio-converted by the gut microbiota to influence pertinent efficiency. Ginsenoside compound K (GCK) is a potential anti-type 2 diabetes (T2D) saponin, which is mainly bio-transformed into protopanaxadiol (PPD) by the gut microbiota. Studies have shown that the gut microbiota between diabetic patients and healthy subjects are significantly different. Herein, we aimed to characterize the biotransformation of GCK mediated by the gut microbiota from diabetic patients and healthy subjects. Based on 16S rRNA gene sequencing, the results indicated the bacterial profiles were considerably different between the two groups, especially Alistipes and Parabacteroides that increased in healthy subjects. The quantitative analysis of GCK and PPD showed that gut microbiota from the diabetic patients metabolized GCK slower than healthy subjects through liquid chromatography tandem mass spectrometry (LC-MS/MS). The selected strain A. finegoldii and P. merdae exhibited a different metabolic capability of GCK. In conclusion, the different biotransformation capacity for GCK may impact its anti-diabetic potency.
